Natco Pharma wins on the launch of Everolimus 10 mg on the US market

Natco Pharma rose 1.90% to Rs 908 after the drug maker launched its Everolimus 10 mg tablets in the US market.

Everolimus is a generic version of Afinitor tablets, used to treat certain types of cancer, tumors and seizures.

According to industry sales data, the 10 mg strength of Infinitor generated annual sales of $ 392 million in the twelve months ending July 2021.

On a consolidated basis, Natco Pharma’s net profit fell 38.6% to Rs 75 crore on a 27.2% drop in net sales to Rs 410.30 crore in the first quarter of June 2021 compared to the first quarter June 2020.

Natco Pharma manufactures a full line of branded and generic dosage forms, bulk actives and intermediates for the Indian and international markets.

Powered by Capital Market – Live News

(This story was not edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear reader,

Business Standard has always strived to provide up-to-date information and commentary on developments that matter to you and have broader political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these difficult times resulting from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative views and cutting edge commentary on relevant current issues.
However, we have a demand.

As we fight the economic impact of the pandemic, we need your support even more so that we can continue to provide you with more quality content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscriptions to our online content can only help us achieve the goals of providing you with even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital editor

Comments are closed.